Kestrel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-05-2024
- Paid Up Capital ₹ 0.95 M
as on 24-05-2024
- Company Age 6 Year, 26 Days
- Last Filing with ROC 31 Mar 2023
- Revenue -15.22%
(FY 2022)
- Profit 39.70%
(FY 2022)
- Ebitda 60.38%
(FY 2022)
- Net Worth -77.49%
(FY 2022)
- Total Assets -30.88%
(FY 2022)
About Kestrel Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M, as per Ministry of Corporate Affairs (MCA) records.
Nisha Prajeesh, Abhilash Thankappan, Manju Krishna, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239KL2018PTC055732
- Company No.
055732
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Nov 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kozhikode, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kestrel Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyesh Parambil  | Managing Director | 29-Nov-2018 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nisha Prajeesh | Director | 20-Feb-2020 | Current |
| Abhilash Thankappan | Director | 15-Oct-2019 | Current |
| Manju Krishna | Director | 12-Mar-2019 | Current |
| Vysakh Nair | Director | 29-Nov-2018 | Current |
Financial Performance of Kestrel Pharmaceuticals.
Kestrel Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 15.22% decrease. The company also saw a substantial improvement in profitability, with a 39.7% increase in profit. The company's net worth observed a substantial decline by a decrease of 77.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kestrel Pharmaceuticals?
Unlock access to Kestrel Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Quedbreak Education Private LimitedInactive For E-Filing 8 months 26 days
Vysakh Nair is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kestrel Pharmaceuticals?
Unlock and access historical data on people associated with Kestrel Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kestrel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kestrel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
